Primary membranous nephropathy with nephrotic syndrome
Methodology & AI Transparency ⓘ
Primary membranous nephropathy with nephrotic syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Primary membranous nephropathy with nephrotic syndrome (N04.21) in Kidney & Renal relies on spot urine albumin-to-creatinine in Primary membranous nephropathy with nephrotic syndrome (N04.21: ratio), guiding step-wise therapeutic adjustments toward eGFR (Creatinine + in Primary membranous nephropathy with nephrotic syndrome (N04.21: Cystatin C)) (>= 90 mL/min/1.73m2 (N04.21)).
- 2 Real-world patient consensus: Clinical coding for Primary membranous nephropathy with nephrotic syndrome uses ICD-10 N04.21 across Kidney & Renal specialty care.
- 3 Typical cash cost range: Clinicians assessing Primary membranous nephropathy with nephrotic syndrome focus on disordered calcium-phosphate-PTH mineral in Primary membranous nephropathy with nephrotic syndrome (N04.21: metabolism) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Primary membranous nephropathy with nephrotic syndrome monitoring tracks Serum Potassium, Bicarbonate in Primary membranous nephropathy with nephrotic syndrome (N04.21: & Phosphorus) toward K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.21).
Ask our AI Specialists anything about Primary membranous nephropathy with nephrotic syndrome
What Is Primary membranous nephropathy with nephrotic syndrome?
Clinical triage of Primary membranous nephropathy with nephrotic syndrome (N04.21) in Kidney & Renal relies on spot urine albumin-to-creatinine in Primary membranous nephropathy with nephrotic syndrome (N04.21: ratio), guiding step-wise therapeutic adjustments toward eGFR (Creatinine + in Primary membranous nephropathy with nephrotic syndrome (N04.21: Cystatin C)) (>= 90 mL/min/1.73m2 (N04.21)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Primary membranous nephropathy with nephrotic syndrome (N04.21), physiological disruption stems from disordered calcium-phosphate-PTH mineral in Primary membranous nephropathy with nephrotic syndrome (N04.21: metabolism), informing Chronic Kidney Disease & Electrolytes protocols that track eGFR (Creatinine + in Primary membranous nephropathy with nephrotic syndrome (N04.21: Cystatin C)) (>= 90 mL/min/1.73m2 (N04.21)).
Common Symptoms & Clinical Signs
- • Presentation of Primary membranous nephropathy with nephrotic syndrome (N04.21): changes in urine in Primary membranous nephropathy with nephrotic syndrome (N04.21: output volume, nocturnal)
- • Secondary Primary membranous nephropathy with nephrotic syndrome clinical sign: asymptomatic decline in in Primary membranous nephropathy with nephrotic syndrome (N04.21: eGFR or persistent)
- • Symptom flares in Primary membranous nephropathy with nephrotic syndrome correlating with Serum Potassium, Bicarbonate in Primary membranous nephropathy with nephrotic syndrome (N04.21: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.21)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Primary membranous nephropathy with nephrotic syndrome (N04.21: ratio) evaluation (N04.21)
Primary membranous nephropathy with nephrotic syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N04.21 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Primary membranous nephropathy with nephrotic syndrome (N04.21: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Primary membranous nephropathy with nephrotic syndrome (N04.21: Cystatin C)) | >= 90 mL/min/1.73m2 (N04.21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Primary membranous nephropathy with nephrotic syndrome (N04.21: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N04.21) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Primary membranous nephropathy with nephrotic syndrome
Treatment selection for Primary membranous nephropathy with nephrotic syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Primary membranous nephropathy with nephrotic syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| 7 Questions to Bring to Your Next Doctor Visit (And Why They Work) Patients who bring a simple written list of 5 to 7 focused questions get clearer answers, leave with fewer medication mix-ups, and feel far more confident about their care plan—without making the appointment run longer. BMJ Quality & Safety / Patient Education and Counseling • 2026-11-01 • Systematic Review | N = 4,820 | 96/100 | PMID 34582101 ↗ |
| New Insights on Modeling Statin-Induced Reductions of heart and blood vessel Events in Primary: What a 6,735-Participant Study Found Our results show that, in individuals without clinical ASCVD, statin therapy has the potential to reduce the frequency of CV events. Cardiology • 2018-01-15 • Meta-Analysis | N = 6,735 | 94/100 | PMID 29705799 ↗ |
| New Insights on Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary: What a 628-Participant Study Found Ezetimibe plus atorvastatin was well tolerated, with a safety profile similar to atorvastatin alone and to placebo. Circulation • 2003-05-20 • Randomized Controlled Trial | N = 628 | 93/100 | PMID 12719279 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
| New Insights on A phase 3, multicenter, randomized, gold-standard blind, vehicle-controlled,: What a 281-Participant Study Found In the sofpironium group, common events (incidence, ≥5%) were nasopharyngitis (14.2%) and dermatitis/skin redness at the application site (8.5%/5.7%), with no serious side effects reported. The Journal of dermatology • 2021-03-15 • Phase III Randomized Trial | N = 281 | 93/100 | PMID 33410265 ↗ |
Primary membranous nephropathy with nephrotic syndrome Patient Community & “People Like Me” Threads
Filter Primary membranous nephropathy with nephrotic syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.